Here are 8 potential reasons why not to prescribe Lixisenatide: 1- this is only one small study and only one dose was tested, 2- Lixisenatide is not currently available at pharmacies, 3- the weight loss associated with this GLP-1 is not desirable in many cases of Parkinsons disease where weight loss is an issue, 4- non-motor outcomes did not change as in other trials, and this will need to be better explained
The Mounjaro story is part of a larger, consumer-driven wave of demand where patients are taking possession of their own access wherever possible
Continuous Support : Once underway, you benefit from 24/7 care coordination, including appointment alerts, prescription updates, and comprehensive service for questions or treatment adjustments
When you combine genetic predisposition insights with baseline biomarkers and your real-world tolerability data, you create a more comprehensive picture for tirzepatide dosing
We usually administer NAD+ on its own